This opportunity funds early-stage development of novel biomedical technologies such as diagnostics, drug delivery methods, biomedical materials, medical imaging, and monitoring devices. It excludes clinical trials and regulatory-focused studies but allows limited feasibility studies involving human subjects. Up to $2 million seed funding is available for U.S.-based small businesses with transformative, high-risk, and scalable innovations. Principal investigators must be employed by the company and commit substantial time to the project.
Eligible applicants are U.S.-based small businesses with fewer than 500 employees, majority owned by U.S. citizens or permanent residents. The principal investigator must be employed at least 20 hours per week by the company and commit 173 hours per six months on the project. Funded work must be per
